Tirbanibulin superior to placebo for actinic keratosis
Covid-19: What happened to randomised controlled trials?
11 February 2021Study: New prostate cancer test could avoid unnecessary biopsies
11 February 2021Tirbanibulin superior to placebo for actinic keratosis
(HealthDay)—Tirbanibulin is superior to vehicle at two months for the treatment of actinic keratosis, but almost half of patients who had a complete response experienced recurrence of lesions at one year, according to a study published in the Feb. 11 issue of the New England Journal of Medicine.
